Epstein-Barr virus-positive multiple myeloma following an ABO incompatible second renal transplantation

ABO incompatible kidney transplant recipients receive higher dose of immunosuppression. Previous data indicate that the incidence of malignancy is not higher in these patients. Compared to the general population, renal transplant recipients are at 4.4-fold higher risk of developing myeloma. We descr...

Full description

Saved in:
Bibliographic Details
Published inIndian journal of nephrology Vol. 26; no. 4; pp. 280 - 283
Main Authors Kirushnan, B, Subbarao, B, Prabhu, P
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow Publications 01.07.2016
Medknow Publications and Media Pvt. Ltd
Medknow Publications & Media Pvt. Ltd
Medknow Publications & Media Pvt Ltd
Subjects
Care and treatment
Case Report
Case studies
Complications and side effects
Epstein-Barr virus
Epstein-Barr virus diseases
Health aspects
Immunotherapy
Kidney transplantation
Multiple myeloma
Organ transplant recipients
Patient outcomes
Risk factors
India
multiple myeloma
Epstein-Barr virus
posttransplant lymphoproliferative disease
renal transplantation
ABO incompatible
Online AccessGet full text

Cover

More Information
Summary:ABO incompatible kidney transplant recipients receive higher dose of immunosuppression. Previous data indicate that the incidence of malignancy is not higher in these patients. Compared to the general population, renal transplant recipients are at 4.4-fold higher risk of developing myeloma. We describe a case of posttransplant multiple myeloma in an ABO incompatible renal transplant recipient of a second graft.
ISSN:0971-4065
1998-3662
DOI:10.4103/0971-4065.168143